The global pollen allergy market is currently valued at USD 5850.8 Million in 2023 and is anticipated to expand at a CAGR of 4.2%. Owing to the technological advances in healthcare the market is likely to propel to USD 8828.6 Million by 2033.
The rising prevalence of allergic disorders and their burden across the globe are likely to drive the growth of the pollen allergy market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 5850.8 Million |
| Projected Forecast Value (2033) | USD 8828.6 Million |
| Global Growth Rate (2023 to 2033) | 4.2% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The pollen allergy market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 4.2% in the above-mentioned forecast period.
Pollens are referred to as mostly consist of tiny particles released by grasses, trees, and plants during their reproductive cycle. These pollen particles can easily gasp by animals and humans which can cause inflammation and irritation to some individuals and this allergy can lead to fever and rhinitis.
Patients with pollen allergy need to be aware of the changes that can occur in their area to help them adapt to changes in the pattern and presentation of disease that may result from climate change. The global pollen allergy market rose at a CAGR of 3.8% from 2018 to 2022.
The rising Prevalence of Allergy and Changing Lifestyle Leading to Decreased Immune Resistance drive the Pollen Allergy Market
The rise in the number of patients suffering from pollen-based allergies and more precisely hay fever drives the growth of the market. Moreover, the growing number of patients especially children is another contributor to escalating the global pollen allergy market. Rapid urbanization in the advancing countries is the major factor that boosts the growth of the pollen allergies market in the forecast period.
Allergy is considered a risk factor for asthma, chronic inflammatory conditions and reduce quality of life. Because of these factors, there is a high need for the treatment of allergies. The global pollen allergy market is expected to show tremendous growth due to increased Pharmaceutical Research and Development spending and biotechnology investment.
The increase in greenhouse gas can result in pollen-induced reparative disease which is further estimated to cushion the growth of the pollen allergies market. Increasing environmental pollution will further provide opportunities for the growth of the pollen allergies market in the coming years.
Increase in Healthcare Spending and Government Initiatives to Drive the Market Growth
Over the past few decades, it has been noted that global per capita healthcare spending has increased considerably owing to the increasing rate of awareness regarding the availability of myriad treatments and diagnostic methods for treating various diseases.
Increasing healthcare spending is likely to result in increasing demand for better quality and rapid diagnostic methods, and in turn, create high growth opportunities for players operating in the treatment of pollen allergies market.
Respiratory disease places a huge burden on society in terms of disability and premature mortality, and also in direct health service costs, drugs prescribed, and the indirect costs related to lost production. Pollen allergy is frequently accompanied by allergic asthma treatment. This condition is also impacting the global pollen allergy market.
In order to increase awareness about allergic rhinitis, several government organizations have started awareness programs. For instance, Allergy UK is the operational name of the British Allergy Foundation that observes allergy awareness week from April 25 to May 1.
Increased Awareness Regarding Allergy Immunotherapy to Hamper the Market Growth
Despite a positive growth trajectory, the global pollen allergy market is facing various challenges that are likely to pose a threat to its growth during the forecast period.
The lack of a permanent cure for grass pollen allergy disease and home-based diagnosis are a few restraints to the growth of the global pollen allergy market. The rise in the preference towards the utilization of biosimilars is further projected to impede the growth of the pollen allergies market in the forecast period.
However, the decrease in the awareness of allergy immunotherapy (AIT) amongst patients might further challenge the growth of the pollen allergies market in the near future
Increasing Rate of Allergic Diseases in the USA to Propel the Market Growth
The USA is estimated to account for over 40% of the North American market in 2023. North America has dominated the global pollen allergy market due to the increased incidence rate of allergies and awareness of therapy.
A study conducted by the American College of Allergy, Asthma & Immunology in 2010 reported that about 16.9 million adults and 6.7 million children were diagnosed with hay fever and its prevalence is increasing by approximately 30% in adults and 40% in children.
The United States Food and Drug Administration 2014 estimated around 30 million people in the United States and 500 million globally suffer from one or other form of hay fever symptoms.
Moreover, the increasing focus on Research and Development to develop novel products to cater to high unmet medical needs is highly impacting the market’s growth.
For instance, GlaxoSmithKline plc announced that the USA Food and Drug Administration (FDA) has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient1, as an over-the-counter (OTC) treatment for temporary relief of the symptoms of hay fever or upper respiratory allergies.2
Rising Prevalence of Respiratory Allergic Disorders Driving Growth in the Europe Market
The Europe pollen allergy market is expected to rise at a CAGR of 4.0% from 2023 to 2033. Europe is expected to have the second-largest market for global pollen allergy market. Increasing awareness among people about diseases is also a major factor that may boost the growth of the market in this region.
Europe dominates the pollen allergies market due to the rise in the prevalence of respiratory allergic disorders. Europe is the fastest-growing market in pollen allergy due to increasing healthcare funding by the government. Moreover, an increase in the need for therapeutics is further anticipated to propel the growth pollen allergies market in the region in the coming years.
The Charity Allergy UK estimated that about 18 million people were found to be affected with grass pollen allergy which is more common among children and teenagers. Symptoms of pollen include frequent sneezing, running or blocked nose, and itchy eyes, and throat. In some instances, it can also lead to loss of senses to smell, facial pain, sweating, and severe headache. People suffering from asthma face even worse symptoms which include tight chest, shortness of breath, coughing, and wheezing.
Advancement in Healthcare to Propel the Market Growth
Asia Pacific is anticipated to expand at the fastest CAGR of 3.8% during the forecast period. Asia Pacific emerged as the fastest-growing region in the pollen allergy market owing to the presence of unmet healthcare infrastructure needs and the increasing prevalence of allergic diseases.
Furthermore, favorable government initiatives in regions like Japan and Australia pertaining to drug price adjustment and the development of novel drugs for the treatment of pollen allergy are expected to provide manufacturers with lucrative future growth opportunities.
| Country | CAGR |
|---|---|
| The UK | 4.0% |
| India | 3.7% |
| South Korea | 3.6% |
| China | 3.8% |
| The USA | 4.2% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Corticosteroids Segment Remains Dominant Among Other Types
Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, and Immunotherapy are the key segments analyzed in the scope of the study.
Corticosteroids dominated the pollen allergy market in 2023 with a revenue share of 35.5%. Corticosteroids are mostly used as the first line of treatment and are also expected to contribute towards the aforementioned conclusion.
Whereas, calcineurin inhibitors are expected to grow at the fastest CAGR during the forecast period owing to their high response rate and the presence of a strong pipeline of calcineurin inhibitors and semi-synthetic analogs of these inhibitors.
Inhaled Allergen SignificantlyDominated the Market
Based on allergen type, the market is categorized into food, inhaled, drug, and others. Inhaled allergens led the global pollen allergy market in 2023 due to increased incidences of respiratory allergies across the globe. The segment is projected to expand further at the fastest CAGR owing to the high demand for allergy testing and the introduction of specific allergens for the detection of pollen allergy.
The drug allergies segment is also expected to register a strong CAGR of 3.8% from 2023 to 2033. Food allergies were the second-largest segment, in terms of revenue share, and are projected to continue the trend throughout the forecast years. Children are more susceptible to these types of allergic diseases. According to the estimates published by the USA National Institute of Health (NIH), the prevalence of food allergies among children is double that of adults.
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the pollen allergy market.
Some of the start-ups in the pollen allergy market include-
The professional survey study carefully analyses the operations and overview of the corporate structures and functioning of the leading and major manufacturers and players functional within the global pollen allergy market. It assesses its product offerings, financial outlook, sales, revenue, and growth over the forecast period.
Some of the leading manufacturers and players assessed in the global pollen allergy market are bioMerieux SA, HOB Biotech Group Corp Ltd, Alcon, HYCOR Biomedical, Inc, Immunomic Therapeutics, Quest Diagnostics Incorporated, Omega Diagnostics Group PLC, Siemens Healthcare Private Limited, Stallergenes Greer, Lincoln Diagnostics, Inc., and others
Manufacturers and players functional in the pollen allergy market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | USD 5850.8 Million |
| ProjectedForecast Value (2033) | USD 8828.6 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Product Type, Allergen Type, Therapeutics Drug Class, End-User, Regions |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC, South Africa, Israel |
| Key Companies Profiled | bioMerieux SA; HOB Biotech Group Corp Ltd; Alcon; HYCOR Biomedical, Inc; Immunomic Therapeutics; Quest Diagnostics Incorporated; Omega Diagnostics Group PLC; Siemens Healthcare Private Limited; Stallergenes Greer; Lincoln Diagnostics, Inc. |
| Customization | Available Upon Request |
The global pollen allergy market is likely to reach a valuation of USD 5850.8 million by the end of 2023.
bioMerieux SA, HOB Biotech Group Corp Ltd, Alcon, HYCOR Biomedical, Inc, and Immunomic Therapeutics are some of the key players in the global pollen allergy market.
Sales of the pollen allergy market are likely to expand at 4.2% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for the pollen allergy market.
By the end of 2033, the global market for pollen allergy market is predicted to reach a valuation of USD 8828.6 Million
| Estimated Market Size (2024E) | USD 22.8 billion |
|---|---|
| Projected Market Value (2034F) | USD 42.7 billion |
| Value-based CAGR (2024 to 2034) | 7.2% |
| Expected Market Value in 2023 | USD 30 billion |
|---|---|
| Projected Market Value in 2033 | USD 50 billion |
| CAGR (2023 to 2033) | 5.2% |
| Expected Market Value (2023) | USD 39.83 Billion |
|---|---|
| Projected Forecast Value (2033) | USD 66.15 Billion |
| Global Growth Rate (2023 to 2033) | 5.2% CAGR |
Explore Therapy Area Insights
View Reports
Pollen Allergy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
